Enveric Biosciences reports Q1 net loss of $2.46M, advances EB-003, signs seven non-binding term sheets

Enveric Biosciences, Inc.

2024-Q1 EPS reported -$0.61 vs consensus -$142.29 ▲ beat (+99.6%)

Net loss $2.46M ($0.61 per diluted share) vs $4.80M ($2.31) in Q1 2023; cash $6.36M.
Seven non-binding term sheets with four partners could yield up to $410M milestones plus future royalties.
Lead asset EB-003 advancing toward IND filing and Phase 1 trial.
Raised $4.5M from warrant exercises in Q1.
Drug discovery platform generated >1,000 proprietary candidates across seven molecule classes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enveric Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income $2.46 million, EPS $0.61.

Period: the first quarter ended March 31, 2024
Net income: $2.46 million
EPS: $0.61
Result: reported results

Exact text from the filing

Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.